Segal Institute participating in CAM2038 trial

The Segal Institute for Clinical Research has announced that it has three investigators participating in the Phase 3 trial of CAM2038, sponsored by Braeburn Pharmaceuticals and Camurus.

CAM2038 is an experimental drug designed to help patients battle their opioid addictions. The investigators participating in the trail hope to produce results that will be beneficial in treating opioid dependence.

In the past 10 years, opioid addiction has become a growing problem in the United States. It is a disease that can lead to overdose and death and only a handful of medicines have been developed to treat it.

The Center for Disease Control and Prevention reported that deaths attributed to opioid addiction reached a record level in 2014, with 29,000 people dying from overdoses. That is almost 80 deaths a day.

CAM2038 is in Phase 3 of its trial period and is designed to be administered to patients by both weekly and monthly dosing options. Phase 3 will see CAM2038 given to patients on a randomized and double-blind basis.

If Phase 3 of the trial is effective, CAM2038 could help combat opioid addiction and reduce the number of deaths each year, revolutionizing the way physicians and patients combat the disease, Segal Institute’s Dr. Rishi Kakar said.